生命科学资讯

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment

FDA clears Encora Therapeutics’ wearable wrist device for essential tremor

What were the biggest clinical trial flops of 2025?

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio

Chutes & Ladders—Sanofi's stunning CEO switch

Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans

'When the markets opened, we were ready': Why biotech IPOs are back for 2026

Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance

Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback

BridgeBio preps approval push after dwarfism drug increases children's height in phase 3

Langer-backed biotech looks to end cancer recurrence with surgical revolution

Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval

Seres to lay off 30% of employees, pause lead program in latest strategic shift

Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma

European VCs join forces to boost flagging biotech investment in the region

UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing